Close

Bristol-Myers Squibb (BMY) Announces Encouraging Data from Urelumab + Opdivo Phase 1/2 in Melanoma

Go back to Bristol-Myers Squibb (BMY) Announces Encouraging Data from Urelumab + Opdivo Phase 1/2 in Melanoma